Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis

Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder

(2012) Andrea Kurzwernhart et al.   CHEMICAL COMMUNICATIONS

Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors

(2012) Shuang Lü et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Metal-based antitumour drugs in the post-genomic era: what comes next?

(2011) Gianni Sava et al.   DALTON TRANSACTIONS

Bioorganometallics: Future Trends in Drug Discovery, Analytical Chemistry, and Catalysis†,‡

(2011) Elizabeth A. Hillard et al.   ORGANOMETALLICS

(Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells

(2010) B. Biersack et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Rational Design of an Organometallic Glutathione Transferase Inhibitor

(2009) Wee Han Ang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Recent developments in ruthenium anticancer drugs

(2009) Aviva Levina et al.   Metallomics

A potential role for protein tyrosine phosphatase inhibition by a RuIII–edta complex (edta = ethylenediaminetetraacetate) in its biological activity

(2008) Debabrata Chatterjee et al.   CHEMICAL COMMUNICATIONS

Bioorganometallic chemistry—from teaching paradigms to medicinal applications

(2008) Christian G. Hartinger et al.   CHEMICAL SOCIETY REVIEWS

New trends for metal complexes with anticancer activity

(2008) Pieter CA Bruijnincx et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Antitumour metal compounds: more than theme and variations

(2007) Michael A. Jakupec et al.   DALTON TRANSACTIONS